FDA approved a new Alzheimer’s drug despite controversy over whether it works
The drug, aducanumab, promises to slow progression of the disease. But some call it false hope
A person with Alzheimer’s disease receives an infusion of the drug aducanumab at Butler Hospital in Providence, R.I., in 2019 as part of a clinical trial. The U.S. Food and Drug Administration approved the drug as a treatment for Alzheimer’s on June 7.
Charles Krupa/AP Images